SCHEMBL9975338

SCHEMBL9975338

CNc1ccc(OCc2ccccc2)c(Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 1/20 0.55
PTPN12 Q05209 1/20 0.55
PTPN13 Q12923 1/20 0.55
SSU72 Q9NP77 1/20 0.55
NPC1 O15118 1/20 0.52
NFKB1 P19838 1/20 0.52
RAB9A P51151 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
EGFR P00533 11/20 0.52
ERBB2 P04626 10/20 0.52
GRM4 Q14833 1/20 0.52
STK10 O94804 1/20 0.52
SLK Q9H2G2 1/20 0.52
PTK6 Q13882 1/20 0.51
MRGPRX4 Q96LA9 2/20 0.47
C5AR1 P21730 1/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28907176 0.85 C5AR1 (0.61) C5AR1MEN1MAPTKMT2A
SCHEMBL13996563 0.85 ACP1 (0.53) ACP1PTPN12PTPN13SSU72NPC1
SCHEMBL6978325 0.85 ERBB2 (0.48) ACP1PTPN12PTPN13SSU72EGFR
SCHEMBL22793766 0.85 PPARA (0.51) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL15304787 0.84 ACP1 (0.55) ACP1PTPN12PTPN13SSU72NPC1
SCHEMBL9975357 0.84 EGFR (0.65) EGFRERBB2
SCHEMBL6962757 0.84 ACP1 (0.55) ACP1PTPN12PTPN13SSU72NPC1
SCHEMBL13994027 0.84 ACP1 (0.52) ACP1PTPN12PTPN13SSU72NPC1
SCHEMBL6978367 0.83 KDR (0.52) EGFRERBB2GRM4PTK6MEN1
SCHEMBL6979978 0.83 FFAR4 (0.54) SMN1; SMN2MRGPRX4C5AR1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202879-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-06-19 US disclosed
US-20090143414-A1 Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity SHIONOGI & CO., LTD. (JP) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143414-A1 Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity ERBB2, EGFR, ABL1 ACP1 635/4885PTPN12 47/4885PTPN13 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.